Evidence map›Paper›PMID 22072423›Full record

ArticleGlia2012

Regulation of proton-coupled folate transporter in retinal Müller cells by the antipsoriatic drug monomethylfumarate.

B Renee Bozard, Paresh P Chothe, Amany Tawfik, Cory Williams, Sadanand Fulzele, Puttur D Prasad, Pamela M Martin, Vadivel Ganapathy, Sylvia B Smith

Abstract read
In one paragraph

Article in Glia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

B Renee BozardDepartment of Cellular Biology and Anatomy, Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia 30912-2000, USA.
Paresh P Chothe
Amany Tawfik
Cory Williams
Sadanand Fulzele
Puttur D Prasad
Pamela M Martin
Vadivel Ganapathy
Sylvia B Smith
Discovery Institute · USAugusta University · US

Funding

Role of homocysteine in retinal diseaseR01EY012830 · NEI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI SMITH, SYLVIA B. · 2000 to 2016
$4.4M
Retinal Iron Homeostasis in Health and DiseaseR01EY019672 · NEI · AUGUSTA UNIVERSITY · PI GANAPATHY, VADIVEL · 2010 to 2013
$1.4M
NEI NIH HHS EY 012830NEI NIH HHS EY 019672NEI NIH HHS R01 EY012830NEI NIH HHS R01 EY019672
6 · The paper itself

Abstract

Fumaric acid esters are used to treat psoriasis, an inflammatory skin disease characterized by keratinocyte proliferation. Inflammation and proliferation are hallmarks of retinal disease; hence, fumaric acid esters may have therapeutic value in retinal pathology. In diseased retinas, Müller glial cells (MCs) undergo reactive gliosis, a hyperproliferative state. MCs take up folate, a vitamin necessary for cell proliferation, via the proton-coupled folate transporter (PCFT). Here we examined the effect of monomethylfumarate (MMF), the active metabolite of fumaric acid esters, on expression and function of PCFT in MCs. Primary MCs, isolated from neonatal mouse retinas, were treated with MMF, and PCFT function was monitored by measuring uptake of radiolabeled methyltetrahydrofolate (MTF) at pH 5.5. Dose-response and time-course analyses were performed to identify optimal conditions for maximal effect. The influence of MMF treatment on kinetic parameters of PCFT was studied, and PCFT expression was analyzed at the mRNA and protein level. MTF uptake in MCs decreased by ˜50% following 18 h treatment with 1 mM MMF. This effect was specific to fumaric acid esters. MMF treatment decreased the maximal velocity of the transporter without altering substrate affinity. The decrease in PCFT function following MMF treatment was accompanied by attenuated PCFT expression. This is the first report that an antipsoriatic compound can regulate folate transport in MCs and may have potential for the treatment of reactive gliosis in retinal disease.

Indexed as

Analysis of VarianceAnimalsAnimals, NewbornAntipsychotic AgentsDermatologic AgentsDose-Response Relationship, DrugFolate Receptor 1FumaratesGene Expression RegulationMaleatesMiceMice, Inbred C57BLNeurogliaNiacinProton-Coupled Folate TransporterReceptors, G-Protein-CoupledAntipsychotic Agentscitraconic acidDermatologic AgentsFolate Receptor 1FumaratesHcar2 protein, mouseMaleatesNiacinProton-Coupled Folate TransporterReceptors, G-Protein-CoupledReceptors, NicotinicRNA, MessengerTritiumVasodilator Agents

Identifiers

PMID22072423
PMCPMC3265662
OpenAlexW2044000997

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.